Post by Aprea Therapeutics

In a new interview with BioPharm International ahead of #BIO2026, our President & CEO, Oren Gilad, PhD, discussed how biomarker-driven strategies are transforming oncology drug development: enabling developers to identify the patients most likely to benefit from a given therapy, potentially improving efficacy while reducing toxicity. At Aprea, this philosophy is built into everything we do. Our APR-1051 WEE1 inhibitor program is designed to address limitations associated with earlier compounds in the class and our clinical strategy includes multiple patient-selection approaches. "The concept of personalized medicine has been proven in the clinic and on the market." — Oren Gilad, PhD Read the full interview here: https://bit.ly/4uZTLxF